Harbour Investments’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLX
Harbour Investments's PLX Position: Q3 2026 in Review
Harbour Investments held its Protalix BioTherapeutics (PLX) position steady in Q3 2026 at 6,000 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2918.
Harbour Investments first reported a position in PLX in Q3 2021 and has held it in 4 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.
- Harbour Investments held 6,000 shares of Protalix BioTherapeutics worth $16.6K as of Q3 2026.
- Harbour Investments left its Protalix BioTherapeutics share count unchanged in Q3 2026.
- Protalix BioTherapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q3 2026, its #2918 holding.
- Harbour Investments first reported a position in Protalix BioTherapeutics in Q3 2021 and has held it in 4 quarters since.
- 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.
Based on Harbour Investments's 13F filing for Q3 2026, filed 9 Nov 2026.